Near tetrapoloid karyotype with translocation t(11;14) in a Moroccan patient with amyloid light-chain amyloidosis and multiple myeloma

Abstract

Cytogenetic and iFISH plays a major part in the diagnosis of the MM and have an important prognostic significance. 10–15% of patients with amyloidosis will also have multiple myeloma (MM). Few studies have addressed the clinical and cytogenetic features of patients with AL amyloidosis with concurrent multiple myeloma. This study of MM case in which we found a near tetraploid complex karyotype with the t(11;14) (q13;q32) abnormality in cytogenetic analysis and the presence of t(4;14) and del(17p) by iFISH, referred to several studies which showed the translocation t(11;14) as the most frequent abnormality in both AL amyloidosis and MM.

Multiple Myeloma: Bioinformatic Analysis for Identification of Key Genes and Pathways

“…65 This most common translocation in MM, t(11; 14) (q13; q32), involves an abnormal fusion of the IGH locus with cyclin D1. 66 Overexpression of cyclin D1 was also observed in 25% to 50% of MM samples, indicating that the deregulation of cyclin D1, which was a critical regulator of the G1/S transition and therefore of the cell cycle, may be a key event in MM development. 67 In the PPI network, IL6 (Interleukin-6) represented the connectivity of 25 interactions.…”

From spear to trident: Upgrading arsenal of CAR-T cells in the treatment of multiple myeloma

“…In addition, current studies seem to support the view that renal function [ 16 ], heart rate and hypertension [ 17 ] are also unneglectable factors when evaluating the survival of MM, which were found to be associated with shorter survival. Nevertheless, by contrast, the most important factor related to prognosis is the cytogenetic abnormal status chiefly assessed by fluorescence in situ hybridization [ [18] , [19] , [20] , [21] ], including but not limited to abnormalities of chromosome 1 (1q gains, 1p losses),t (4, 14) (p16, q32), t(14, 16) (q32, q23), deletion of 17p13 and chromosome 22, which are associated with worse prognosis. Of note, cytogenetic abnormalities were not necessarily associated with shortened survival.…”